BioMarin's Foray into Oncology with Lead Therapeutics Acquisition
By Taskin Ahmed
Pharma Deals Review: Vol 2010 Issue 2 (Table of Contents)
Published: 12 Feb-2010
DOI: 10.3833/pdr.v2010.i2.1313 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
BioMarin Pharmaceutical has signed an agreement to acquire Lead Therapeutics to gain the latter’s early stage poly (ADP-ribose) polymerase (PARP) inhibitor, LT-673...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS